Scholars@Duke publication: Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.

Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.

Publication , Journal Article

Corbett, KS; Gagne, M; Wagner, DA; O' Connell, S; Narpala, SR; Flebbe, DR; Andrew, SF; Davis, RL; Flynn, B; Johnston, TS; Stringham, CD; Wu, K ...

Published in: Science (New York, N.Y.)

December 2021

Published version (DOI)

Neutralizing antibody responses gradually wane against several variants of concern (VOCs) after vaccination with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine messenger RNA-1273 (mRNA-1273). We evaluated the immune responses in nonhuman primates that received a primary vaccination series of mRNA-1273 and were boosted about 6 months later with either homologous mRNA-1273 or heterologous mRNA-1273.β, which encompasses the spike sequence of the B.1.351 Beta variant. After boost, animals had increased neutralizing antibody responses across all VOCs, which was sustained for at least 8 weeks after boost. Nine weeks after boost, animals were challenged with the SARS-CoV-2 Beta variant. Viral replication was low to undetectable in bronchoalveolar lavage and significantly reduced in nasal swabs in all boosted animals, suggesting that booster vaccinations may be required to sustain immunity and protection.

Duke Scholars

Author Chris Stringham

Published In

Science (New York, N.Y.)

DOI

10.1126/science.abl8912

EISSN

1095-9203

ISSN

0036-8075

Publication Date

December 2021

Volume

374

Issue

6573

Start / End Page

1343 / 1353

Related Subject Headings

Virus Replication
Vaccine Efficacy
Th1 Cells
T Follicular Helper Cells
SARS-CoV-2
RNA, Viral
Nose
Memory B Cells
Macaca mulatta
Immunogenicity, Vaccine

Citation

APA

Chicago

ICMJE

MLA

NLM

Corbett, K. S., Gagne, M., Wagner, D. A., O’ Connell, S., Narpala, S. R., Flebbe, D. R., … Seder, R. A. (2021). Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science (New York, N.Y.), 374(6573), 1343–1353. https://doi.org/10.1126/science.abl8912

Corbett, Kizzmekia S., Matthew Gagne, Danielle A. Wagner, Sarah O’ Connell, Sandeep R. Narpala, Dillon R. Flebbe, Shayne F. Andrew, et al. “Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.” Science (New York, N.Y.) 374, no. 6573 (December 2021): 1343–53. https://doi.org/10.1126/science.abl8912.

Corbett KS, Gagne M, Wagner DA, O’ Connell S, Narpala SR, Flebbe DR, et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science (New York, NY). 2021 Dec;374(6573):1343–53.

Corbett, Kizzmekia S., et al. “Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.” Science (New York, N.Y.), vol. 374, no. 6573, Dec. 2021, pp. 1343–53. Epmc, doi:10.1126/science.abl8912.

Corbett KS, Gagne M, Wagner DA, O’ Connell S, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham CD, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O’Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Yang ES, Wang L, Choe M, Boyoglu-Barnum S, Wei S, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd J-PM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, Seder RA. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science (New York, NY). 2021 Dec;374(6573):1343–1353.

Published In

Science (New York, N.Y.)

DOI

10.1126/science.abl8912

EISSN

1095-9203

ISSN

0036-8075

Publication Date

December 2021

Volume

374

Issue

6573

Start / End Page

1343 / 1353

Related Subject Headings

Virus Replication
Vaccine Efficacy
Th1 Cells
T Follicular Helper Cells
SARS-CoV-2
RNA, Viral
Nose
Memory B Cells
Macaca mulatta
Immunogenicity, Vaccine